



## *Press Release*

### **Hon'ble High Court of Hyderabad approved the merger of Auctus Pharma with Granules India.**

**Hyderabad, November 13, 2014:** Granules India Ltd., a fast growing pharmaceutical manufacturing company, announced that the Hon'ble High Court of Judicature at Hyderabad for the State of Telangana & Andhra Pradesh has sanctioned the Scheme of Amalgamation whereby Auctus Pharma Limited (Wholly – Owned Subsidiary) stands amalgamated with Granules India Limited. Certified true copy of the Court order was filed with Registrar of Companies on 13th November, 2014 with appointed date of April 1, 2013.

Auctus Pharma was a public limited and unlisted company incorporated on 25th April 2000 located at Hyderabad. Auctus Pharma was the manufacturer and seller of bulk drugs and intermediates. It has two manufacturing facilities, an API facility in the Pharmacity in Vishakhapatnam and an Intermediate facility in Hyderabad. The API facility has approvals from leading regulatory agencies including the U.S. FDA, EDQM, Health Canada, KFDA and WHO-GMP. Auctus' product portfolio includes twelve APIs and two intermediates. The portfolio includes APIs in several therapeutic categories such as Antihistamine, Antihypertensive, Antithrombotic and Anticonvulsant as well as other therapeutic categories.

#### **About Granules India Ltd. (BSE: 532482, NSE: GRANULES)**

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Granules has the largest PFI facility in the world with an industry leading 6 ton batch size. The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

Granules has strengthened its advantages through its Operational Excellence (OE) department which looks at every step of the manufacturing process in order to gain efficiencies and has also implemented systems that have standardized quality and reduced variation. The Company's OE program is regularly cited by MNCs as a "best in class" program and is the comparative advantage that lets Granules provide world-class quality products at a lower cost than its competitors. The adoption of the OE philosophy by Granules has earned it several recognitions including The Economic Times Manufacturing Excellence Awards 2011.

#### **Caution Statement:**

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

#### **Contacts:**

Gayatri Ganesh  
Genesis Burson-Marsteller  
+91 9703700884  
[gayatri.ganesh@bm.com](mailto:gayatri.ganesh@bm.com)